Calculating halving time of the BCR-ABL transcript after 3 months may help determine prognosis in chronic myeloid leukaemia (CML) patients undergoing first-line tyrosine kinase inhibitor (TKI) therapy ...
Although all authors completed the disclosure declaration, the following author(s) indicated a financial or other interest that is relevant to the subject matter under consideration in this article.
Researchers have found that the clinical application of BCR::ABL1 digital PCR can reliably quantify stable deep molecular remission of chronic myeloid leukemia (CML), which will help to determine for ...
Researchers have found that the clinical application of BCR::ABL1 digital PCR can reliably quantify stable deep molecular remission of chronic myeloid leukemia (CML), which will help to determine for ...
BOULDER, Colo., Nov. 3, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback